Bicycle Therapeutics

BCYC

Market cap $499M

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Bicycle Therapeutics plc ("Bicycle" or the "Company") (NASDAQ: BCYC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

New York, New York--(Newsfile Corp. - November 18, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Bicycle Therapeutics plc ("Bicycle Therapeutics plc") (NASDAQ: BCYC) concerning possible violations of federal securities laws. On October 31, 2025, RBC Capital Markets analyst Leonid Timashev downgraded Bicycle to Sector Perform from Outperform, citing delays in development of zelenectide pevedotin, which is in phase 2/3 development for metastatic urothelial cancer, due to pushing dose selection to the first quarter of 2026.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, Nov. 18, at 10:30 a.m. GMT. A live webcast of the fireside chat will be accessible from the Investor section of the company's website at w.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate updates. “We are currently seeking broad regulatory feedback to make an informed decision on our path forward with zelenectide pevedotin in metastatic ur.

Bicycle Therapeutics (BCYC) remains a compelling investment, trading below cash value despite promising early data for its lead asset, zelenectide pevedotin. Zelenectide pevedotin shows comparable efficacy to enfortumab vedotin in urothelial cancer, with manageable toxicity and ongoing expansion into other Nectin-4-amplified tumors. BCYC's strong cash position and planned workforce reduction extend operational runway into 2028, reducing near-term financial risk despite high burn rates.

Bicycle Therapeutics plc (NASDAQ:BCYC ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Kevin Lee - CEO & Executive Director Jennifer Perry - Chief Strategy Officer & Head of Commercial Alethia Young - Chief Financial Officer Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst Hello, everyone. I'm Max Skor, a biotech analyst with Morgan Stanley, and I'm happy to welcome Bicycle Therapeutics, specifically Kevin Lee, CEO; Alethia Young, CFO; and Jennifer Perry, Chief Strategy Officer.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointments of Roger Dansey, M.D., and Hervé Hoppenot to the company's Board of Directors. "We are thrilled to welcome Roger and Hervé to our Board of Directors as we make strong progress across our pipeline and anticipate numerous upcoming mi.

Bicycle (BCYC) Q2 Revenue Falls 69%

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. “We continue to execute on our strategy, which is grounded in scientific rigor and focused on fulfilling our mission to develop next-generation prec.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on July 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 77,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering i.